SCHEMBL7474682

SCHEMBL7474682

CCCCCCCc1cnc(Cl)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 1/20 0.49
MAPT P10636 3/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
STAT3 P40763 1/20 0.46
ATM Q13315 1/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
PTGS2 P35354 4/20 0.44
ESR1 P03372 2/20 0.44
ADRA2A P08913 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8126315 1.00 RARB (0.49) RARBMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL8552636 1.00 RARB (0.49) RARBMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL4478012 1.00 RARB (0.49) RARBMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL2249764 0.98 RARB (0.46) RARBMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL12760430 0.91 NFKB1 (0.46) RARBMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL303902 0.82 NPC1 (0.40) MAPTRAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL28055917 0.81 RARB (0.50) RARBMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL12186156 0.81 RARB (0.50) RARBMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL12186163 0.81 RARB (0.50) RARBMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL25801708 0.80 RARB (0.46) RARBMAPTRAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993754-B2 Iridium complex and light emitting material formed from same NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2015-03-31 US disclosed
EP-2471800-B1 IRIDIUM COMPLEX AND LIGHT EMITTING MATERIAL FORMED FROM SAME NAT INST OF ADVANCED IND SCIEN (JP) 2014-01-15 EP disclosed
US-20120208999-A1 IRIDIUM COMPLEX AND LIGHT EMITTING MATERIAL FORMED FROM SAME NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2012-08-16 US disclosed
EP-2471800-A1 IRIDIUM COMPLEX AND LIGHT EMITTING MATERIAL FORMED FROM SAME National Institute of Advanced Industrial Science And Technology (JP) 2012-07-04 EP disclosed
EP-1214306-A1 LIQUID CRYSTAL COMPOUNDS Qinetiq Limited (GB) 2002-06-19 EP disclosed
WO-2001021606-A1 LIQUID CRYSTAL COMPOUNDS QINETIQ LIMITED (GB) 2001-03-29 WO disclosed
EP-0409634-A2 Liquid crystal compounds and optically active compounds SANYO CHEMICAL INDUSTRIES LTD. (JP) 1991-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208999-A1 IRIDIUM COMPLEX AND LIGHT EMITTING MATERIAL FORMED FROM SAME LUC7L2, CRY1, INTS9 RARB 3014/4885MAPT 668/4885RAB9A 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.